Latest G-Finder report on global funding status for neglected diseases

A recent report, out on 9 December 2014, highlighted a significant drop in the global investment into the research and development within the field of neglected disease. The seventh Global Funding of Innovation for Neglected Diseases survey, or G-Finder – a report on the global investments into the research and development of new global health and neglected disease products – showed that there a cut of $193m in investment on the previous year.

G-FINDER is a comprehensive report to date on public and private funding into R&D for neglected diseases like malaria, TB, HIV, pneumonia, sleeping sickness and helminth infections. The survey covers 34 neglected diseases, 138 product development areas such as drug, vaccine, diagnostic and vector control development, as well as platform technologies and all product-related R&D.

On a positive note, funding for product development partnerships (PDPs) increased by a $28m this year after dropping for the past four years. This is largely due to the UK Department for International Development (DFID)’s new five-year PDP funding stream. PDPs are an essential part of the development of new tools to fight neglected diseases, and have been behind 70% of all new neglected disease drugs and vaccines developed since 2000.

Find out more about the G-Finder report.